Novo Nordisk's Ozempic gets FDA approval for kidney disease
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of ...
Novo’s Ozempic Notches Approval for Kidney Disease, Widening Use
Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...
pharmaphorum21h
Novo Nordisk grabs NASH drug from Ventus in $703m deal
Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...
HSBC to wind down M&A and ECM capabilities in Europe, UK & Americas, memo shows
HSBC is preparing to wind down its M&A and equity capital markets businesses in Europe, the UK and the Americas as part of a ...
pharmaphorum21h
Novo Nordisk nears EU okay for oral GLP-1 drug Rybelsus after CHMP nod
The new oral drug is viewed as a key product for Novo Nordisk as it tries to case Eli Lilly's Trulicity (dulaglutide), a once-weekly GLP-1 drug that is the market leader in the class with sales of ...
Bloomberg L.P.20h
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...